SCHEMBL4328848

SCHEMBL4328848

NC(=S)NN=Cc1cc(F)c(N2CC[C@@H](NCc3cccc(F)c3)C2)cc1F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TMEM97 Q5BJF2 1/20 0.46
SIGMAR1 Q99720 1/20 0.46
CARM1 Q86X55 2/20 0.43
PRMT6 Q96LA8 2/20 0.43
MAOB P27338 2/20 0.43
GAA P10253 2/20 0.36
KDM4E B2RXH2 1/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
MPI P34949 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
BCHE P06276 2/20 0.36
ACHE P22303 2/20 0.36
BACE1 P56817 2/20 0.36
TEAD1 P28347 2/20 0.36
ALDH1A1 P00352 2/20 0.36
KMT2A Q03164 2/20 0.36
HCRTR1 O43613 1/20 0.36
CYP1A2 P05177 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4328846 1.00 TMEM97 (0.46) TMEM97SIGMAR1CARM1PRMT6MAOB
SCHEMBL4338687 1.00 TMEM97 (0.46) TMEM97SIGMAR1CARM1PRMT6MAOB
SCHEMBL13611881 1.00 TMEM97 (0.46) TMEM97SIGMAR1CARM1PRMT6MAOB
SCHEMBL4338690 1.00 TMEM97 (0.46) TMEM97SIGMAR1CARM1PRMT6MAOB
SCHEMBL4329139 0.92 MAOB (0.44) TMEM97SIGMAR1MAOBGAAKDM4E
SCHEMBL4327749 0.92 MAOB (0.44) TMEM97SIGMAR1MAOBGAAKDM4E
SCHEMBL4327756 0.92 MAOB (0.44) TMEM97SIGMAR1MAOBGAAKDM4E
SCHEMBL4322290 0.92 MAOB (0.44) TMEM97SIGMAR1MAOBGAAKDM4E
SCHEMBL4331381 0.90 BCHE (0.41) TMEM97SIGMAR1MAOBGAABCHE
SCHEMBL4329387 0.90 BCHE (0.41) TMEM97SIGMAR1MAOBGAABCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 TMEM97 784/4885SIGMAR1 948/4885CARM1 2651/4885
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 TMEM97 720/4885SIGMAR1 776/4885CARM1 2677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.